Loading
Epigenetics and DNA Methylation / Cancer Related Molecular Mechanisms Research · Journal article
Molecular Cancer · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study proposing that site-specific m6A demethylation of ZBTB7A via a targeted RNA m6A erasure system suppresses colorectal cancer cell migration in vitro. The work identifies a putative regulatory axis (METTL3/ZBTB7A/ARHGAP26) and demonstrates proof-of-concept for precise m6A editing as a potential therapeutic modality, but lacks in vivo efficacy, clinical translation, and quantitative effect size data.
Journal article. Colorectal cancer cells. Intervention: Targeted RNA m6A erasure (TRME) system achieving site-specific demethylation at m6A_site_411666 within ZBTB7A mRNA.
ZBTB7A identified as an m6A-modified transcription factor that promoted CRLM via multi-omics integration METTL3-mediated m6A modification of ZBTB7A enhanced translation and expression via YTHDF1/3 reader complex recognition Site-specific demethylation at m6A_site_411666 within ZBTB7A mRNA suppressed CRC cell migration without perturbing global m6A abundance
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical work suggests m6A-targeted epigenetic editing may offer a non-pharmacological approach to chemoresistant colorectal cancer metastasis, but requires in vivo validation, toxicity assessment, and clinical translation before informing patient care.
Mechanistic study identifying a putative therapeutic target (m6A site-specific demethylation of ZBTB7A) in colorectal cancer metastasis using multi-omics and cell-based assays, but lacking in vivo efficacy data or clinical validation.
As stated by the source record.
This preclinical work suggests m6A-targeted epigenetic editing may offer a non-pharmacological approach to chemoresistant colorectal cancer metastasis, but requires in vivo validation, toxicity assessment, and clinical translation before informing patient care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer liver metastasis (CRLM) is the primary cause of CRC-related mortality, with inevitable chemoresistance to targeted therapies and immunotherapy. N 6 -methyladenosine (m 6 A), as a crucial epigenetic regulator of gene expression and cellular physiology, involved in the pathogenesis of CRLM. Precise manipulation of m 6 A modifications could offer a non-pharmacological precision treatment for many diseases. However, the precise editing of m 6 A modification in regulating CRLM progression remains elusive. Here we integrated multi-omics and identified zinc finger and BTB domain-containing 7A (ZBTB7A) as an m 6 A-modified transcription factor that promoted CRLM. Mechanistically, METTL3-mediated m 6 A modification of ZBTB7A facilitated recognition by the m 6 A reader YTHDF1/3 complex, enhancing its translation and expression. This m 6 A-dependent regulation promoted CRLM progression via activation of the ARHGAP26/Rho GTPase signaling axis. Notably, we applied a targeted RNA m 6 A erasure (TRME) system to achieve site-specific demethylation at a single site (m 6 A_site_411666) within ZBTB7A mRNA, without perturbing m 6 A abundance. Temporal demethylation at this site is sufficient to inhibit the CRC cell migration. This study unveils the critical role of the METTL3/ZBTB7A/ARHGAP26 axis in the process of m 6 A-mediated CRLM and positions m 6 A precise editing as a promising therapy in the preclinical treatment of CRLM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.